Trump team moves to ease testosterone rules
2026-06-20
Regulation, not science, takes center stage as the Trump administration seeks to unwind federal limits on testosterone therapy. A draft proposal circulating inside health agencies would scale back Food and Drug Administration guidance that tightened prescribing after studies linked some formulations to elevated cardiovascular risk and erythrocytosis, the abnormal rise in red blood cell mass.
Supporters argue the current framework overshoots the evidence and blocks access for men with clinically confirmed hypogonadism, pointing to endocrinology data that distinguish age‑related decline from primary testicular failure and pituitary dysfunction. They want broader discretion for clinicians, fewer boxed warnings on drug labels, and a narrower definition of what counts as an off‑label, lifestyle prescription in insurance audits.
Critics counter that the rollback reads less like nuanced pharmacovigilance and more like culture war, warning that relaxed controls could spur aggressive direct‑to‑consumer marketing, higher rates of polycythemia, and more unmonitored use in gyms and online gray markets. Hovering over the policy fight is a simple, unresolved question: how much uncertainty a government is willing to accept when it starts rewriting the chemistry of aging bodies.
Loading...
